Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.
Luigi GargiuloLuciano IbbaPiergiorgio MalagoliAnna G BurroniAndrea ChiricozziPaolo DapavoSilvia M FerrucciMassimo GolaMaddalena NapolitanoMichela OrtoncelliMaria T RossiClaudio SciarroneAntonio CostanzoAlessandra NarcisiPublished in: Dermatology and therapy (2024)
Given the wide use of JAKi in clinical practice, it is crucial to establish a specific follow-up for each patient's phenotype in order to achieve the best possible clinical outcome and minimize potential adverse events.